Dr. Reddy’s confirms Naloxone Hydrochloride Injection launch in the US
Category: #health  By Saipriya Iyer  Date: 2020-03-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

Dr. Reddy’s confirms Naloxone Hydrochloride Injection launch in the US

Dr. Reddy’s Laboratories ,along with its subsidiaries, recently announced that the company has unveiled Naloxone Hydrochloride Injection USP, a prefilled Syringe of single-dose of 2mg/2mL which is a generic version of Narcan Injection USP, approved by the U.S. Food and Drug Administration.

Dr Reddy’s Laboratories’ Chief Executive Officer at North America Generics, Marc Kikuchi stated that the firm is looking forward to rolling out its second product in the market which has already been designated as a CGT (Competitive Generic Therapy) by the U.S. Food and Drug Administration.

Kikuchi further added that the company will have a 180-day of CGT exclusivity on account of the CGT designation to market the product.

According to reliable sources, the Naloxone Hydrochloride Injection USP, 2mg/2mL (1mg/mL) witnessed sales of $31 million MAT across the United States for all the past twelve months up till January 2020.

Apparently, the drug is mainly used to block any effects made by opioids. It is mostly used to reduce the breathing pattern when overdosed on opioid. Naloxone also has the ability to be used in combination with an opioid to lower the risks of misuse of the substances.

Citing sources familiar with the matter, the shares belonging to Dr. Reddy's Laboratories had been slogging down to 3.20% at Rs 2582.45 as the stock has crashed by 10.63% in four different sessions from the closing high of about Rs 2889.90, which had been recorded last on 13 March 2020.

For the record, Dr. Reddy's Laboratories is a pharmaceutical firm based in India. The company provides a vast portfolio of products as well as services with the help of its three different businesses covering global genetics, proprietary products, and pharmaceutical active ingredients and services.

The services provided by the company include custom pharmaceutical services (CPI), differentiated formulations, new chemical entities, generics, active pharmaceutical ingredients (API), and biosimilars.

Source Credit- https://www.business-standard.com/article/news-cm/dr-reddy-s-labs-launches-naloxone-hydrochloride-injection-in-us-120031900747_1.html



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Russia to start clinical trial of novel COVID-19 vaccine in 2 weeks
Russia to start clinical trial of novel COVID-19 vaccine in 2 weeks
By Saipriya Iyer

Russia has recently announced its plan to start the clinical trials of the potential COVID-19 vaccine within a period of two weeks.

The health ministry in Russia has recently inform...

AdaptHealth enters definitive deals to acquire Solara & ActivStyle
AdaptHealth enters definitive deals to acquire Solara & ActivStyle
By Saipriya Iyer

AdaptHealth Corp. has recently entered two separate definitive agreements for the acquisition of Solara Medical Supplies, LLC and ActivStyle, Inc. AdaptHealth is a leading home medical supplies, equipment, and other re...

Ambani’s JioMart unveils a new website to deliver orders across India
Ambani’s JioMart unveils a new website to deliver orders across India
By Saipriya Iyer

Jio Platforms, the top telecom operator along with Jio Retail, which is the top retail chain has recently unveiled JioMart’s new website and has begun taking orders in a large amount from tier 1, tier 2 and metro c...